Which patients need an axillary clearance after sentinel node biopsy?

Area of Science:

• Oncology
• Surgical Oncology
• Pathology

Background:

• Sentinel lymph node biopsy (SLNB) is a standard procedure for staging axillary lymph nodes (ALN) in breast cancer patients with clinically negative axillae.
• SLNB minimizes morbidity by avoiding unnecessary axillary lymph node dissection (ALND) in patients without nodal metastasis.
• Current guidelines recommend completion ALND for detected macro- and micrometastases in SLNB, but its necessity is debated.

Purpose of the Study:

• To evaluate the clinical significance and prognostic implications of minimal metastatic disease detected by SLNB.
• To question the routine recommendation for completion ALND following positive SLNB, particularly in cases of isolated tumor cells (ITCs) or micrometastasis.
• To analyze the impact of SLNB findings on local recurrence and overall survival.

Main Methods:

• Review of current literature and guidelines regarding SLNB and ALND in breast cancer management.
• Analysis of the Z0011 trial's preliminary results concerning outcomes after SLNB versus completion ALND.
• Discussion of the prognostic value of isolated tumor cells (ITCs) and micrometastases identified in SLNB.

Main Results:

• SLNB is a safe and accurate method for staging ALN, reducing surgical morbidity.
• The benefit of completion ALND after positive SLNB (macro- or micrometastasis) is under debate.
• Preliminary Z0011 trial data suggest comparable outcomes between SLNB and ALND when the sentinel node is positive, warranting cautious interpretation.

Conclusions:

• The management of the axilla in patients with minimal SLNB metastasis (ITCs, micrometastasis) requires further clarification.
• The prognostic significance of minimal SLNB metastasis regarding local recurrence and survival is controversial.
• Further research and interpretation of trials like Z0011 are crucial for refining axillary staging and treatment guidelines.